



GAU 1632 ~~1~~

Box Seq

ATTORNEY DOCKET NO. 01097.0008U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 20 2001

In re Application of)

MULLAN)

Serial No. 09/785,951)

Filed: February 16, 2001)

For: TEST AND MODEL FOR ALZHEIMER'S)
DISEASE)

Group Art Unit: 1632

Examiner: Unassigned

TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner of Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200
The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

August 13, 2001

Sir:

This is responsive to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated April 11, 2001.
A copy of the Notice is enclosed.



ATTORNEY DOCKET NO. 01097.0008U2
SERIAL NO. 09/785,951

Also enclosed is a diskette containing the Sequence Listing for this application in computer readable form (CRF) and a paper copy of the Sequence Listing in compliance with 37 C.F.R. §§ 1.821-1.825. Applicants hereby certify that the information in both the computer readable form and the paper copy of the Sequence Listing enclosed herewith is the same and includes no new matter.

A check in the amount of \$195.00 (extension of time fee) is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
[404] 688-0770

CERTIFICATE OF MAILING

I hereby certify that this COMMUNICATION is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on the date shown below.

Gwendolyn D. Spratt

8-13-01
Date



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 20 2001

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/785,951 | 02/16/2001 | Michael John Mullan | 01097.0008U2 |

CONFIRMATION NO. 7348

FORMALITIES LETTER



OC000000005955964



Wendolyn D. Spratt, Esq.
 NEEDLE & ROSENBERG, P.C.
 The Candler Building, Suite 1200
 127 Peachtree Street, N.E.
 Atlanta, GA 30303-1811

Date Mailed: 04/11/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED

AUG 20 2001

TECH CENTER 1600/2900

#4
OIPE

RAW SEQUENCE LISTING

DATE: 08/28/2001

PATENT APPLICATION: US/09/785,951

TIME: 12:19:14

Input Set : A:\01097.0088U2.TXT

Output Set: N:\CRF3\08282001\I785951.raw

4 <110> APPLICANT: Mullan, Michael
6 <120> TITLE OF INVENTION: Test and Model for Alzheimer's Disease
9 <130> FILE REFERENCE: 01097.00018U2
11 <140> CURRENT APPLICATION NUMBER: 09/785,951
12 <141> CURRENT FILING DATE: 2001-02-16
14 <150> PRIOR APPLICATION NUMBER: 09/058,384
15 <151> PRIOR FILING DATE: 1998-04-09
17 <150> PRIOR APPLICATION NUMBER: 08/808,126
18 <151> PRIOR FILING DATE: 1997-02-28
20 <150> PRIOR APPLICATION NUMBER: 08/478,197
21 <151> PRIOR FILING DATE: 1995-06-07
23 <150> PRIOR APPLICATION NUMBER: 08/094,547
24 <151> PRIOR FILING DATE: 1993-02-19
26 <150> PRIOR APPLICATION NUMBER: 07/894,211
27 <151> PRIOR FILING DATE: 1992-06-04
29 <160> NUMBER OF SEQ ID NOS: 3
31 <170> SOFTWARE: FastSEQ for Windows Version 4.0
33 <210> SEQ ID NO: 1
34 <211> LENGTH: 8
35 <212> TYPE: PRT
36 <213> ORGANISM: Artificial Sequence
38 <220> FEATURE:
39 <223> OTHER INFORMATION: Description of Artificial Sequence; Note =
40 Synthetic Construct
42 <221> NAME/KEY: VARIANT
43 <222> LOCATION: 4-5
44 <223> OTHER INFORMATION: Xaa = can be any amino acid except Lys and/or Xaa
45 = can be any amino acid except Met
47 <400> SEQUENCE: 1
W--> 48 Ser Glu Val Xaa Xaa Asp Ala Glu
49 1 5
51 <210> SEQ ID NO: 2
52 <211> LENGTH: 44
53 <212> TYPE: DNA
54 <213> ORGANISM: Artificial Sequence
56 <220> FEATURE:
57 <223> OTHER INFORMATION: Description of Artificial Sequence; Note =
58 Synthetic Construct
60 <400> SEQUENCE: 2
61 cagactgaga tcccagaacc ctaggtctga ctctagggtc ttgg 44
63 <210> SEQ ID NO: 3
64 <211> LENGTH: 48
65 <212> TYPE: DNA
66 <213> ORGANISM: Artificial Sequence
68 <220> FEATURE:
69 <223> OTHER INFORMATION: Description of Artificial Sequence; Note =
70 Synthetic Construct

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/785,951

DATE: 08/28/2001

TIME: 12:19:14

Input Set : A:\01097.0088U2.TXT

Output Set: N:\CRF3\08282001\I785951.raw

72 <400> SEQUENCE: 3

73 cagactgaga tcccagaacc gatcctaggt ctgactctag ggtcttgg

48

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/785,951

DATE: 08/28/2001

TIME: 12:19:15

Input Set : A:\01097.0088U2.TXT

Output Set: N:\CRF3\08282001\I785951.raw

L:48 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1